WebFeb 27, 2024 · Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression … WebJan 26, 2024 · Stoke’s TANGO technology is based on ASOs, which are small fragments of modified RNA designed to bind to specific regions of pre-mRNA, thus reducing non-productive mRNA and boosting protein production. In addition to SCN1A, three other disease-related genes were identified as ASO candidates.
Stoke Therapeutics LinkedIn
WebJan 10, 2024 · About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing … WebJan 9, 2024 · BEDFORD, Mass. -- (BUSINESS WIRE)--Jan. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ... Read More For media inquiries, please contact: Dawn Kalmar Chief Communications Officer [email protected] philip hampton dermatology
Stoke Therapeutics Presents Preclinical Data That ... - BioSpace
WebMay 2, 2024 · Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. WebJan 10, 2024 · TANGO (Targeted Augmentation of Nuclear Gene Output) is Stoke’s proprietary research platform. Stoke’s initial application for this technology are diseases in which one copy of a gene... WebAug 10, 2024 · As a result of the business combination, Tango Therapeutics expects to receive gross proceeds of approximately $342 million, which consists of cash proceeds of approximately $156 million from BCTG ... true xc5 hockey gloves